Literature DB >> 18550

Ribonucleotide reductase from herpes simplex virus (types 1 and 2) infected and uninfected KB cells: properties of the partially purified enzymes.

M Ponce de Leon, R J Eisenberg, G H Cohen.   

Abstract

Mammalian ribonucleotide reductase is a complex enzyme modified in its activity by a complex regulatory system involving adenosine triphosphate (ATP) and deoxyribonucleoside triphosphates. Infection of KB cells with herpes simplex virus (HSV) type 1 or 2 induces the formation of an altered ribonucleotide reductase. The properties of partially purified reductase from uninfected KB cells have been compared with the enzymes obtained from HSV-1 and HSV-2 infected KB cells. We found that the virus-induced enzymes are similar to the KB enzyme in some properties but differed significantly from the host enzyme in three respects: (1) virus induced reductase was not inhibited significantly by deoxythymidine triphosphate regardless of ATP concentration, (2) magnesium was not required for virus enzyme activity although 2 mM-Mg2+ did stimulate the reaction, and (3) magnesium concentration required for optimal activity was different for virus and host enzymes. These changes are evidence that the enzyme molecules present after infection by HSV-1 or HSV-2 differ from those present before infection.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 18550     DOI: 10.1099/0022-1317-36-1-163

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  19 in total

1.  Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir.

Authors:  D M Coen; D J Goldstein; S K Weller
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  Neutralization of herpes simplex virus ribonucleotide reductase activity by an oligopeptide-induced antiserum directed against subunit H2.

Authors:  E A Cohen; P Gaudreau; P Brazeau; Y Langelier
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

3.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

4.  Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.

Authors:  C R Brandt; B Spencer; P Imesch; M Garneau; R Déziel
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Strategic design and three-dimensional analysis of antiviral drug combinations.

Authors:  M N Prichard; L E Prichard; C Shipman
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

6.  Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1.

Authors:  D R Averett; P A Furman; T Spector
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

7.  Partial purification and characterization of the ribonucleotide reductase induced by herpes simplex virus infection of mammalian cells.

Authors:  D Huszar; S Bacchetti
Journal:  J Virol       Date:  1981-02       Impact factor: 5.103

8.  Induction of a new ribonucleotide reductase after infection of mouse L cells with pseudorabies virus.

Authors:  H Lankinen; A Gräslund; L Thelander
Journal:  J Virol       Date:  1982-03       Impact factor: 5.103

9.  Capacity of deoxycytidine to selectively antagonize cytotoxicity of 5-halogenated analogs of deoxycytidine without loss of antiherpetic activity.

Authors:  L M Fox; J A Mekras; C B Bagwell; S B Greer
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

10.  Differential effect of nucleoside analog triphosphates on ribonucleotide reductases from uninfected and herpes simplex virus-infected HeLa cells.

Authors:  K Nakayama; J L Ruth; Y C Cheng
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.